ClinicalTrials.gg

Program

netarsudil

Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.

Furthest: phase 4, since Jan 10, 201920 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon180 open or runningphase 4since Jan 10, 2019Feb 5, 2012none ahead
Price Vision Group20 open or runningphase 3since May 30, 2019May 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Feb 5, 2012.

  1. Mar 12, 2015Phase 1 study in Healthy SubjectsAlcon · NCT02406287 · 10 enrolled · United States
  2. Sep 16, 2015Phase 3 study in Glaucoma, Open-AngleAlcon · NCT02558374 · 708 enrolled · United States
  3. Aug 15, 2016Phase 2 study in Ocular HypertensionAlcon · NCT02874846 · 12 enrolled · United States
  4. Jul 12, 2017Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03233308 · 20 enrolled · United States
  5. Aug 29, 2017Phase 3 study in Glaucoma, Open-AngleAlcon · NCT03284853 · 436 enrolled · Austria, Belgium, Czechia and more
  6. Oct 13, 2017Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03310580 · 42 enrolled · United States
  7. Jan 10, 2019Phase 4 study in Glaucoma, Open-AngleAlcon · NCT03808688 · 261 enrolled · United States
  8. Feb 15, 2019Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03844945 · 215 enrolled · Japan
  9. May 30, 2019Price Vision Group's first study: phase 3 study in Fuchs' Endothelial DystrophyNew to Price Vision GroupPrice Vision Group · NCT03971357 · 19 enrolled · United States
  10. Aug 7, 2019Phase 3 study in Fuchs' Endothelial DystrophyPrice Vision Group · NCT04051463 · 29 enrolled · United States
  11. Jul 31, 2020Phase 2 study in Corneal EdemaAlcon · NCT04498169 · 40 enrolled · United States
  12. Oct 26, 2020Phase 3 study in Glaucoma, Open-AngleAlcon · NCT04620135 · 245 enrolled · Japan
  13. Mar 7, 2022Phase 4 study in GlaucomaAlcon · NCT05283395 · 136 enrolled · United States
  14. Jul 17, 2025Phase 3 study in Ocular HypertensionAlcon · NCT07082816 · 489 enrolled · United States

TargetBeta

ROCK1 →ROCK2 →read by rule
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
belumosudilruleSanofiphase 426

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07082816Ocular Hypertension · United States3CompletedAlconApr 6, 2026489
NCT05283395Glaucoma · United States4CompletedAlconMar 22, 2023136
NCT04620135Glaucoma, Open-Angle · Japan3CompletedAlconJul 9, 2021245
NCT04498169Corneal Edema · United States2CompletedAlconAug 11, 202140
NCT04051463Fuchs' Endothelial Dystrophy · United States3CompletedPrice Vision GroupJul 1, 202029
NCT03971357Fuchs' Endothelial Dystrophy · United States3TerminatedPrice Vision GroupAug 26, 202119
NCT03844945Glaucoma, Open-Angle · Japan2CompletedAlconSep 19, 2019215
NCT03808688Glaucoma, Open-Angle · United States4CompletedAlconJul 26, 2019261
NCT03310580Glaucoma, Open-Angle · United States2CompletedAlconOct 25, 201842
NCT03284853Glaucoma, Open-Angle · Austria, Belgium, Czechia and more3CompletedAlconNov 6, 2020436
NCT03233308Glaucoma, Open-Angle · United States2CompletedAlconApr 19, 201820
NCT02874846Ocular Hypertension · United States2CompletedAlconSep 201612
NCT02558374Glaucoma, Open-Angle · United States3CompletedAlconDec 2016708
NCT02406287Healthy Subjects · United States1CompletedAlconApr 201610
NCT02246764Ocular Hypertension · United States3CompletedAlconDec 201693
NCT02207621Ocular Hypertension · United States3CompletedAlconMar 2016756
NCT02207491Ocular Hypertension · United States3CompletedAlconMar 2015411
NCT01997879Healthy · United States1CompletedAlconNov 201318
NCT01731002Ocular Hypertension · United States2CompletedAlconMay 2013224
NCT01528787Ocular Hypertension · United States2CompletedAlconJul 201285

How it is read

Names in the registry

  • “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
  • “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
  • “Netarsudil ophthalmic solution 0.02%”, 2 entries
  • “Netarsudil Ophthalmic”, 2 entries
  • “AR-13324 Ophthalmic Solution 0.04%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.